News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


LCT Parkinson’s trial resumes patient recruitment

LCT Parkinson’s trial resumes patient recruitment

23 June 2014 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited today announced that it has received the necessary regulatory approval to resume recruitment of the remaining three patients in the Phase I/IIa clinical trial of NTCELL® in Parkinson’s disease. The trial was paused in December last year while the company completed internal and external audit and regulatory processes.

Dr Ken Taylor, NTCELL Program Director and Acting Chief Executive, is pleased that patient recruitment in the clinical trial of NTCELL for Parkinson’s can resume.

“The completion of the clinical trial is an initial step in progressing NTCELL to commercialisation as the first disease modifying treatment for Parkinson’s disease.”

Existing treatments for Parkinson’s treat the symptoms rather than attempting to regenerate the affected brain cells. Many people with Parkinson’s no longer respond to these treatments.

“LCT is committed to developing and marketing NTCELL for Parkinson’s patients not responding to current therapies. We also intend to further investigate the potential of our patented cell therapy as a treatment for other neurodegenerative disorders,” said Dr Taylor.

Preclinical studies which confirmed NTCELL initiated nerve growth support the development of NTCELL as a potential treatment for other neurological diseases such as Huntington’s, Motor Neuron and Alzheimer’s.

For further information: www.lctglobal.com

About Living Cell Technologies
Living Cell Technologies (LCT) is an Australasian biotechnology company researching and developing cell therapies to treat diseases with high unmet clinical need. LCT’s lead product NTCELL® is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory producing nerve growth factors to promote new central nervous system growth and repair disease induced nerve degeneration.

NTCELL is in Phase I/IIa clinical trial in New Zealand for the treatment of Parkinson’s disease. It has the potential to be used in a number of indications.

LCT’s proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its research and development, operations and manufacturing facilities based in New Zealand.

For more information visit www.lctglobal.com or follow @lctglobal on Twitter

ENDS

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Fringe Review: Rossum’s Universal Robots

Written in 1920 by Karel Capek in a newly independent Czechoslovakia, its prophetic tale of artificial intelligence, automata and human morality was initially a big hit, but it then vanished from view, in New Zealand at least, before being revived in Hamilton last year. More>>

SELECT FRINGE SHOWS:

Pictures Of Media: Call For Photographs For Reimagining Journalism

In August this year Freerange Press is launching its next big book. This time we are gathering the best writers and thinkers in the country to look at the changing media landscape in New Zealand. To illuminate and give voice to the writing we want to include around 25 excellent photos. We want these photos to document the different aspects of how journalism is made, how it used to be, and how it is changing. More>>

Safer Internet Day: Keeping Safe Online More Important Than Ever

Tuesday 9 February marks Safer Internet Day. Safer Internet Day is designed to create awareness about the importance of Internet safety and encourages positive use of technology - with a strong focus on young people. More>>

ALSO:

We Have The Technology: Zephyrometer Up And Moving

“The needle’s stoppers had to be repaired because of the extra impact caused by the balance not being correct. We also added an extra 300kgs counter-balance – made from zinc coated steel triangle plates. These adjustments will now stop it bending low over the road in high winds.” More>>

ALSO:

Waitangi Day: Treaty Of Waitangi - Found In Translation

To celebrate the Society of Translators and Interpreters's 30th anniversary, over 90 translators will work together to translate the English and Māori versions of the Treaty of Waitangi into 30 languages... More>>

ALSO:

Northland Development: Trust Applauds $4m Government Funding For Art Centre

Today's announcement of central government support, made by Minister of Economic Development Steven Joyce, provides a key step forward in funding for Whangarei’s Hundertwasser Art Centre & Wairau Maori Art Gallery. More>>

ALSO:

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news